Austedo vs Vyepti
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Austedo | US Vyepti | |
|---|---|---|
| Generic name | deutetrabenazine | eptinezumab |
| Drug class | VMAT2 Inhibitor | Anti-CGRP Monoclonal Antibody |
| Treats | Tardive dyskinesia, Huntington's chorea | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Teva | Lundbeck |
| Year approved | 2017 | 2020 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $150M | — |
| Common side effects | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth | Stuffy nose and sore throat, Allergic reactions, Fatigue |
Frequently asked questions
Is Austedo or Vyepti better?
Neither is universally "better." Austedo (deutetrabenazine) and Vyepti (eptinezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Austedo and Vyepti?
Austedo is a VMAT2 Inhibitor made by Teva, while Vyepti is a Anti-CGRP Monoclonal Antibody made by Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Austedo has the larger estimated TV advertising budget of the two.